DNYUZ
No Result
View All Result
DNYUZ
No Result
View All Result
DNYUZ
Home News

The first pill to slow Alzheimer’s could come from an unexpected place

November 17, 2026
in News
The first pill to slow Alzheimer’s could come from an unexpected place

BOSTON — Alzheimer’s drug research is littered with failures. But this week, clinicians delivered some unexpectedly positive news, courtesy of a Viagra-like pill that has been repurposed for the brain disease.

The drug, already sold as Mvix in South Korea for erectile dysfunction, slowed mental decline in a year-long global trial of more than 1,500 people with early Alzheimer’s — but only in those who weren’t already taking other dementia drugs.

For those patients, who made up about 40 percent of the study population, a lower-dose version of Mvix eased the disease’s march by nearly a third compared with a dummy pill. The measure is based on interviews with patients and their caregivers about memory, judgment and the ability to handle daily life.

In other words, after a year, people on the drug were roughly where the placebo group had been about 3½ months earlier, according to the company’s estimate. If the effect holds, the time saved could keep growing with each year of treatment.

The rest of the trial told a different story, though. In the other 60 percent of subjects — people who were already taking standard medications to manage symptoms such as memory loss and confusion — the drug showed little to no benefit. As a result, across the full group, the effect disappeared.

Despite the mixed picture, the trial’s sponsor says the outcome is a success. AriBio, the South Korean company developing the drug for Alzheimer’s, had specified in advance that it would judge the results two ways: in everyone and in people not taking other dementia medicines. A win in either group would then count as meeting the study’s main goal.

AriBio said it plans to discuss with the FDA whether the data can stand on their own or whether the agency will want another trial first.

Outside experts such as Atticus Hainsworth, a neuroscientist at City St George’s, University of London, are cautiously optimistic. “It’s early days to say much definitively,” said Hainsworth, who was not involved in the Alzheimer’s study but is evaluating the AriBio drug for another brain condition, one affecting small blood vessels that is a common cause of stroke and dementia. But the evidence so far in people not taking other dementia drugs “looks pretty good to me,” he said.

If approved for Alzheimer’s, the low-dose formulation of Mvix would be the first pill authorized in the United States to slow the disease, said Sharon Sha, a neurologist who directs the Stanford Center for Memory Disorders and led the trial.

Existing treatments either temporarily ease symptoms while the underlying decline continues unabated, or are antibody therapies that slow the disease about as much as Mvix did in trial participants not on other dementia drugs but must be given by infusion or injection and carry a risk of brain swelling and bleeding.

“So, to have a disease-modifying drug with relatively minimal side effects that is oral would be huge,” said Sha, who presented the findings Monday at the Clinical Trials on Alzheimer’s Disease conference. “It’s very exciting and promising.”

A leap from the bedroom to the brain would be a fitting second act for Mvix. After all, reinvention is nothing new for Viagra and its chemical cousins.

These drugs all work the same way. They disable an enzyme called phosphodiesterase type 5 that normally shuts off a chemical signal telling blood vessels to relax. With that off switch jammed, the signal lingers, which for men with erectile dysfunction means more blood can rush into the penis during arousal and stay there.

Yet that same signal also operates in the brain, where it flips on a molecular switch that nerve cells use to reinforce their connections, a key step in locking in memories. Keep it on longer, the thinking goes, and an ailing brain might get a boost.

It was the blood-vessel effect that first caught researchers’ attention. In the early 1990s, Pfizer tested an experimental pill of this kind as a treatment for angina, the chest pain caused by poor blood flow to the heart.

The drug did little for the heart. But men in early studies reported an unexpected side effect: erections. The FDA approved the drug as Viagra in 1998.

The first hints of a link to the brain came later, from rodent studies in which the drugs improved memory in mice bred to develop features of Alzheimer’s disease. Analyses of medical records then suggested the effect might carry over to people.

One study of insurance claims for more than 7 million Americans found that people taking Viagra were 69 percent less likely to develop Alzheimer’s over six years. Another study of nearly 270,000 British men with erectile dysfunction found an 18 percent lower risk among those prescribed Viagra, Cialis and similar therapies.

But studies like these can’t prove cause and effect. And not all drugs in this class may be equally good at reaching the brain and finding their mark.

AriBio thought it had an edge. Lab studies showed its drug was about 10 times as precise as Viagra at hitting its common target, and the company says it also gets into the brain more readily.

In late 2022, AriBio began testing its pill in memory clinics across North America, Europe and Asia.

AriBio chose a daily dose of 30 milligrams, less than a third of the 100 milligrams most men take for erectile dysfunction. That was enough to act on the brain, the company reasoned, but low enough to avoid side effects that might tip participants off to whether they were getting the real drug.

The bet appears to have paid off. After a year of treatment, people who weren’t taking other dementia medications declined more slowly. Tests of participants’ spinal fluid showed that the drug was reaching its target in the brain. And among those not on other dementia drugs, the therapy lowered levels of a disease-linked form of tau, a protein that contributes to the toxic tangles that build up in Alzheimer’s.

Side effects of the AriBio treatment included diarrhea, dizziness and fainting.

As for the quirk that made Viagra famous? Only three of the roughly 770 people taking the drug reported a boost in libido, perhaps because the dose was well below what’s used for erectile dysfunction.

Then there’s the puzzle hanging over the whole trial: Why did the pill help only those who weren’t already on other dementia drugs? “We all have that question right now,” Sha said.

It could be that the pill’s effects overlap with those of standard dementia drugs, leaving little room for added benefit. Or people already taking those medications, a somewhat larger share of whom had progressed from very mild to mild dementia, may simply have been harder to help.

Whatever the reason, AriBio now has to make its case to regulators. “The primary objective was met,” said Fred Kim, the company’s managing director. “But whether it’s sufficient for approval is a matter of discussion.”

If there’s a path forward, he said, “we’re going to go for it. If there isn’t, then what can we do? We’re going to find out.”

The post The first pill to slow Alzheimer’s could come from an unexpected place appeared first on Washington Post.

Worried about your aging parents living alone? Here’s when to step in.
News

Worried about your aging parents living alone? Here’s when to step in.

by Washington Post
November 17, 2026

By 2060, the number of Americans age 65 and older is expected to be nearly double what it was in ...

Read more
News

Welcome to New York City’s Tech Bro-hemia

November 17, 2026
News

AI Told These Ex-Google Guys How to Build a Billion-Dollar Weapons Business

November 17, 2026
News

The first pill to slow Alzheimer’s could come from an unexpected place

November 17, 2026
News

Trump’s plane screw-up is a gift from decades of GOP plotting

November 17, 2026
After years of attacks, LGBTQ voters are ready for some wins

After years of attacks, LGBTQ voters are ready for some wins

November 17, 2026
You submitted your early college applications: Here’s what you need to do next

You submitted your early college applications: Here’s what you need to do next

November 17, 2026
Trump Goons’ Secret Clashes Before Big Overseas Trip Exposed

Trump Goons’ Secret Clashes Before Big Overseas Trip Exposed

November 17, 2026

DNYUZ © 2026

No Result
View All Result

DNYUZ © 2026